An open-label assessment of TMC 125 - A new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

AIDS

Volumn 17, Issue 18, 2003, Pages

  Gazzard, Brian G ^a   Pozniak, Anton L ^a   Rosenbaum, Willy ^b   Yeni, G Patrick ^c   Staszewski, Schlomo ^d   Arasteh, Keikawus ^e   De Dier, Karin ^f   Peeters, Monika ^f   Woodfall, Brian ^f   Stebbing, Justin ^a   Vant' Klooster, Gerben A E ^a,f  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b HÔPITAL ROTHSCHILD   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e MARTIN LUTHER KRANKENHAUS   (Germany)

^f TIBOTEC BVBA   (Belgium)

Author keywords

HIV; NNRTI; Pharmacokinetic; Resistance; TMC 125

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; FLATULENCE; HEADACHE; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INSOMNIA; MALE; OPEN STUDY; PRIORITY JOURNAL; RASH; STEADY STATE; THORAX PAIN; TREATMENT FAILURE; VIRUS LOAD;

ADULT; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 12144287763     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200312050-00001     Document Type: Article

References (15)

1. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA, 3rd. Complete mutagenesis of the HIV-1 protease. Nature 1989, 340:397-400.
2. Wainberg MA, Gu Z, Gao Q, et al. Clinical correlates and molecular basis of HIV drug resistance. J Acquir Immune Defic Syndr 1993, 6(Suppl 1):S36-S46.
3. Hammer SM. Increasing choices for HIV therapy. N Engl J Med 2002, 346:2022-2023.
4. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001, 26 (Suppl 1):S25-S33.
5. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002, 186:181-188.
6. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002, 4:59-63.
7. Munoz JL, Parks WP, Wolinsky SM, Korber BT, Hutto C. HIV-1 reverse transcriptase. A diversity generator and quasispecies regulator. Ann N Y Acad Sci 1993, 693:65-70.
8. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988, 242:1168-1171.
9. Brenner BG, Turner D, Wainberg MA. HIV-1 drug resistance: can we overcome? Expert Opin Biol Ther 2002, 2:751-761.
10. Temiz NA, Bahar I. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 2002, 49:61-70.
11. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc 2003, 125:6016-6017.
12. Gruzdev et al., AIDS Res Hum Retroviruses (in press).
13. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
14. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002, 18:835-838.
15. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001, 32:774-782.